LIVN LivaNova PLC
USHealthcareAs of 2026-07-10 16:00
Why LIVN matters now
LivaNova PLC (LIVN) is a US stock in Healthcare. The latest InvestLog snapshot shows $82.56 with +0.05% on the session and $4.54B in market capitalization; recent performance reads 1-month +7.65% and YTD +27.58%.
The latest financial table shown here is Q1 2026, with revenue of $362.3M, net income of $22.3M, and EPS of $0.40. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 3.7%.
The latest indexable market news headline is "LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $80.50; recent insider activity includes Zurbay Donald filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.54
P/S
3.01
EV/EBITDA
19.05
DCF Value
$-13.27
FCF Yield
3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.6%
Operating Margin
14.2%
Net Margin
7.5%
ROE
9.1%
ROA
4.3%
ROIC
10.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $362.3M | $22.3M | $0.40 |
| Q4 2025 | $360.9M | $30.9M | $0.57 |
| FY 2025 | $1.39B | $-242.5M | $-4.45 |
| Q3 2025 | $357.8M | $26.8M | $0.49 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$79.67
Target (Median)
$80.50
Target Range
$66.00 - $90.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
GB
Exchange
—
Beta
0.88
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.